Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?
Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM diagnosis and therapeutic strategy mainly rely on direct bone marrow (BM) assessment. Given the MM het...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2022-01-01
|
| Seri Bilgileri: | Hemato |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/2673-6357/3/1/6 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|